OBIO Pre-CAAP Company: HCell Granted Orphan Drug Designation by FDA for Alopecia Areata in Pediatric Population

OBIO Pre-CAAP company HCell Inc., a biotechnology company focusing on Alopecia Areata in the Pediatric Population, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to HC017AA for the treatment of pediatric patients with Alopecia Areata, a devastating hair loss disease.

The granting of Orphan Drug Designation by the U.S. FDA is a significant milestone for HCell in the HC017AA development program. We are working diligently to prepare for the clinical study for this significant, yet unmet, medical need for Alopecia Areata in pediatric patients.
— Jae Hyun Lim M.D., Ph.D, Co-Founder and Chief Science Officer, HCell